Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes

Kristine Secnik Boye  
_Eli Lilly and Company_

Louis S. Matza  
_Center for Health Outcomes Research at UBC_

Alan Oglesby  
_Eli Lilly and Company_

Karen Malley  
_Malley Research Programming, Inc._

Sunny Kim  
_Department of Epidemiology, Florida International University_

See next page for additional authors

Follow this and additional works at: [http://digitalcommons.fiu.edu/epidemiology](http://digitalcommons.fiu.edu/epidemiology)
Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes

Kristina Secnik Boye∗1, Louis S Matza2, Alan Oglesby1, Karen Malley3, Sunny Kim4, Risa P Hayes1 and Robert Brodows1

Address: 1Eli Lilly and Company, Indianapolis, IN 46285, USA, 2Center for Health Outcomes Research at UBC, Bethesda, MD 20814, USA, 3Malley Research Programming, Inc., Rockville, MD, USA and 4School of Public Health, Florida International University, USA

Email: Kristina Secnik Boye∗ - boye_kristina_secnik@lilly.com; Louis S Matza - louis.matza@unitedbiosource.com; Alan Oglesby - oglesby_alan@lilly.com; Karen Malley - k甘malley@comcast.net; Sunny Kim - skim@fiu.edu; Risa P Hayes - hayes_clarice@lilly.com; Robert Brodows - brodows_robert_g@lilly.com

∗ Corresponding author

Abstract

Background: Patient-reported measures can be used to examine whether drug differences other than clinical efficacy have an impact on outcomes that may be important to patients. Although exenatide and insulin glargine appear to have similar efficacy for treatment of type 2 diabetes, there are several differences between the two treatments that could influence outcomes from the patient's perspective. The purpose of the current study was to examine whether the two drugs were comparable as assessed by patient-reported outcomes using data from a clinical trial in which these injectable medications were added to pre-existing oral treatment regimens.

Methods: Patients were randomized to either twice daily exenatide or once daily insulin glargine during a 26-week international trial. At baseline and endpoint, five patient-reported outcome measures were administered: the Vitality Scale of the SF-36, The Diabetes Symptom Checklist – Revised (DSC-R), the EuroQol EQ-5D, the Treatment Flexibility Scale (TFS), and the Diabetes Treatment Satisfaction Questionnaire (DTSQ). Change from baseline to endpoint was analyzed within each treatment group. Group differences were examined with General linear models (GLMs), controlling for country and baseline scores.

Results: A total of 549 patients with type 2 diabetes were enrolled in the trial, and current analyses were conducted with data from the 455 per protocol patients (228 exenatide and 227 insulin glargine). The sample was primarily Caucasian (79.6%), with slightly more men (55.2%) than women, and with a mean age of 58.5 years. Paired t-tests found that both treatment groups demonstrated statistically significant baseline to endpoint change on several of the health outcomes instruments including the DSC-R, DTSQ, and the SF-36 Vitality subscale. GLMs found no statistically significant differences between groups in change on the health outcomes instruments.

Conclusion: This analysis found that both exenatide and insulin glargine were associated with significant improvements in patient-reported outcomes when added to oral medications among patients with type 2 diabetes. Despite an additional daily injection and a higher rate of gastrointestinal adverse events, treatment satisfaction in the exenatide group was comparable to that of the glargine group, possibly because of weight reduction observed in patients treated with exenatide.
Background

In clinical trials, patient-reported outcome measures can complement clinical outcomes by providing information beyond traditional efficacy and safety measures. When new treatments have comparable efficacy, patient-reported instruments can be used to examine whether drug differences other than clinical efficacy have an impact on outcomes that may be important to patients [1]. Two injectable treatments for patients with type 2 diabetes, insulin glargine and exenatide, have been found to have comparable efficacy as measured by HbA1c reduction in a recent 26-week randomized controlled trial [2]. When added to oral medications in this trial, both exenatide and insulin glargine reduced HbA1c levels by 1.1%. Insulin, in conventional and analog forms, is a commonly used treatment for such patients [3,4]. Insulin glargine is a long-acting analog with absorption kinetics that provides a relatively consistent basal insulin supplied for approximately 24 hours [5,6]. Exenatide is a recently approved medication that elicits several of the glucoregulatory actions of glucagon-like peptide-1, an incretin hormone that is an essential regulator of normal glucose homeostasis [2,7-14]. Exenatide has post-parandial and fasting blood glucose effects [2]. Although exenatide and insulin glargine appear to have similar efficacy for reduction of HbA1c, there are several differences between the two treatments that could influence outcomes from the patient’s perspective. Therefore, the purpose of the current study was to conduct a secondary analysis of clinical trial data to examine whether the two drugs were comparable as assessed by patient-reported outcomes.

One difference between these two medications that could lead to differences in patient-reported outcomes is that they have different effects on patients’ body weight. Whereas insulin is associated with increased risk of weight gain [15-17], exenatide has repeatedly been found to be associated with weight reduction [7,8,11,12,14]. For example, in a 26-week head-to-head clinical trial, insulin glargine-treated patients had a mean body weight increase of 1.8 kg from a baseline mean of 88.3 kg, whereas exenatide-treated patients decreased in body weight by 2.3 kg from a baseline mean of 87.5 kg [2]. Weight reduction is likely to lead to positive health outcomes for many patients as it has been shown to improve glycemic control and reduce long-term health risks [16,18-21]. Furthermore, lower weight has been found to be associated with greater patient-reported treatment satisfaction and health-related quality of life (HRQL) among patients with diabetes [22-24]. HRQL can be defined as the patient’s subjective perception of the impact of health status on physical, psychological, and social functioning [1,25].

Exenatide and insulin also differ in side effect profiles. In clinical trials, the most frequent adverse events reported by patients with exenatide have been gastrointestinal side effects, such as nausea and to a lesser extent vomiting, that tend to occur early in treatment [2,7,8,11,12,14]. These gastrointestinal symptoms are generally found to be mild-to-moderate, and they have only a negligible contribution to the weight effects of exenatide [26,27]. Patients treated with insulin glargine have reported a lower incidence of these side effects [2]. Another difference between the two drugs involves dose frequency. Insulin glargine is administered once per day, whereas exenatide is administered twice per day. In general, reduced dose frequency is thought to be associated with greater treatment satisfaction, although there are exceptions for some patients, diseases, and medications [28-32]. To assess the potential impact of these differences between exenatide and insulin glargine, the current study analyzed change in five patient-reported outcome measures, using data from a clinical trial in which the two drugs had comparable efficacy [2]. These outcome measures assessed HRQL, treatment satisfaction, vitality, treatment flexibility, and impact of diabetes symptoms.

Methods

Data source

Data from a 26-week, multicenter, comparator-controlled, open-label, randomized, two-arm, clinical trial were used for this analysis. Data were collected in 13 countries (Australia, Belgium, Brazil, Finland, Germany, Norway, Poland, Portugal, Puerto Rico, Spain, Sweden, the Netherlands, and the United States). All patients were required to have type 2 diabetes that was inadequately controlled with orally administered sulfonylurea and metformin (i.e., HbA1c between 7.0% and 10.0%). Patients were randomized to add one of two injectable medications to their oral treatment regimen: exenatide (taken twice-daily, 15 minutes before morning and evening meals; fixed dose of 5 micrograms bid for the first 4 weeks and subsequently increased to 10 micrograms bid) or insulin glargine (forced titration to FBS target ≤5.5 mmol/L; administered once daily at bedtime). The oral medications were maintained at pre-study dose levels unless patients experienced hypoglycemia, in which case a 50% reduction in sulfonylurea dose was recommended. The primary objective of the study was to test the hypothesis that glycemic control, as measured by change in HbA1c, achieved with exenatide is non-inferior to that of insulin glargine. The current secondary analysis was conducted to compare the two treatment groups with respect to change in patient-reported health outcomes measures. Clinical findings, dropout rates for each treatment group, reasons for study withdrawal, and further description of the trial design are published elsewhere [2].
Measures
In this trial, patients completed five health outcomes instruments at baseline (week 0) and endpoint (week 26), including two generic and three condition-specific measures. Because generic and condition-specific measures have different strengths, it is often recommended to include both types of instruments in clinical trials [33-36]. Compared with generic measures, the primary advantage of condition-specific measures is that they are frequently found to be more responsive to treatment-related change [37]. An advantage of generic PROs is that they can be used to compare among various populations, make comparisons to the general population, and estimate the relative impact of various medical conditions or treatments [1,38-40]. In addition, generic measures usually assess impact of disease and treatment on overall functioning or a broader range of health domains than condition-specific measures [34,39].

Diabetes Symptom Checklist – revised (DSC-R)
The DSC-R is a revised version of the DSC-2, which was developed to measure both the frequency and perceived discomfort of physical and psychological symptoms associated with type 2 diabetes and its potential complications [41]. On the 34 items of the DSC-R, participants first indicate whether they have experienced each symptom in the past month by circling "yes" or "no". If "yes" is selected, the participant proceeds to rate the perceived discomfort of the symptom on a 5-point scale ranging from 1 (not at all) to 5 (extremely). When participants report not having the symptom, the item is scored as zero. The instrument yields a total score and the following subscales: Fatigue, Cognitive, Pain, Sensory, Cardiology, Ophthalmology, Hypoglycemia, and Hyperglycemia. Higher scores indicate greater symptom burden. The total score and all dimension scores range from 0 to 5, with higher scores indicating greater discomfort. The DSC-2 has been found to have good internal consistency reliability, test-retest reliability, construct validity, and responsiveness [41,42]. No published literature on the psychometric properties of the DSC-R was located.

Diabetes Treatment Flexibility Scale (TFS)
The TFS is comprised of 10 items from the 142-item Diabetes Quality of Life Clinical Trial Questionnaire (DQLCTQ), which was designed to assess HRQL among patients with type 1 and type 2 diabetes in multinational clinical trials [43]. The 10 TFS items evaluate how much choice patients have in their decisions concerning meals and physical, social, and other daily activities during the past four weeks [43]. Five questions focus on meals, while the other five focus on activities. Each item is answered on a 5-point Likert scale. The TFS score ranges from 0 to 100, with higher scores indicating greater flexibility. The instrument has demonstrated good internal consistency reliability and discriminant validity [43,44].

Diabetes Treatment Satisfaction Questionnaire (DTSQ)
The DTSQ was designed to measure satisfaction with diabetes treatment regimens among patients with type 1 or type 2 diabetes [22,45]. The instrument is comprised of eight items, each rated on a 7-point Likert scale ranging from 0 to 6. Six of the items contribute to a treatment satisfaction score, and the other two items assess perceived frequency of hyperglycemia and hypoglycemia. On the satisfaction scale, which ranges from 0 to 36, higher scores indicate greater satisfaction. On the hyperglycemia and hypoglycemia items, higher scores indicate greater problems. The current study used the "status form" of the DTSQ (which measures satisfaction at one point in time), as opposed to the "change form" (which measures change in satisfaction) [46]. The instrument has been used to measure outcomes of diabetes management and clinical trials, and it has been shown to be reliable, and valid, and sensitive to change [22,29,45,46].

EuroQol EQ-5D
The EQ-5D is a brief questionnaire that is commonly used to provide an estimate of overall health status in large-scale surveys, clinical research, and health economic evaluation [47]. The EQ-5D descriptive system consists of five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension is assessed by one item with three response choices: no problems, some problems, and severe problems. These five ratings are used to derive the weighted EQ-5D index score, a single score representing overall health with higher scores indicating better health status. An index score of 1 corresponds to perfect health, and 0 corresponds to death, although negative scores representing health states worse than death are possible [48,49]. Reliability, validity, and responsiveness of the EQ-5D have been demonstrated in general population samples as well as samples of patients with a wide range of medical conditions [47]. Mean scores for general samples of patients with type 2 diabetes in previous studies range from roughly 0.69 to 0.77 [50-52]. Scores tend to be somewhat lower among patients with complications, patients being treated with insulin, patients with obesity, and older patients.

Vitality scale of the SF-36 (medical outcomes study short form-36 item health survey)
The SF-36 was created to collect health status information across a variety of diseases and treatment groups [53,54]. The instrument was designed to be appropriate for use in a variety of settings including clinical practice, clinical research, health policy evaluations, and general population surveys. The SF-36 consists of 8 subscales, but only...
the 4-item vitality subscale was administered in the current trial to assess energy level and fatigue. The four items are rated on 6-point Likert scales: two items that are worded positively (“Did you feel full of pep”; “Did you have a lot of energy”) and two items that are worded negatively (“Did you feel worn out”; “Did you feel tired”). Scores range from 0 to 100, with higher scores reflecting less fatigue and greater energy. Reliability and validity of SF-36 scales have been evaluated in multiple studies and have generally been found to be acceptable [54,55]. Mean subscale scores for patients with type 2 diabetes have typically ranged from approximately 40 to 60 in previous studies, and scores have been shown to improve with treatment [56,57]. Vitality scores have also been shown to decline with the onset of diabetes complications [58].

**Statistical analysis**

This analysis was conducted with the per protocol sample, which included all patients who had at least 12 weeks of exposure to study medication and no violations of inclusion/exclusion criteria or discontinuation criteria (e.g., 1.5% increase in HbA1c, more than 10 consecutive days of study medication are missed, or a female patient becomes pregnant). For patients who completed the endpoint analysis earlier than week 26, a last observation carried forward (LOCF) approach was used (i.e., substituting data gathered at week 12, 18, or 26).

Categorical demographic and clinical variables are presented in terms of frequency and percents, whereas continuous variables are summarized in terms of means and standard deviations. To evaluate within-group change in each health outcomes measure, paired t-tests were conducted to compare baseline and endpoint scores. To examine differences between the two treatment groups, general linear models were performed, controlling for country and baseline score. The dependent variable in each model was the health outcome measure change score (endpoint – baseline). Separate models were conducted for each instrument’s total and subscale scores. Finally, because exenatide was associated with a higher incidence of nausea than insulin glargine [2], change in treatment satisfaction (as measured by the DTSQ) was also assessed separately among subgroups of exenatide-treated and insulin glargine-treated patients who experienced nausea at any time during the trial. Results of all analyses were considered statistically significant at a level of p < 0.05. Because these analyses were considered exploratory, no adjustments for multiple comparisons were made.

**Results**

A total of 549 patients were enrolled in the trial. The current analyses were conducted with data from the 455 patients that were considered per protocol (228 exenatide and 227 insulin glargine). Demographic and clinical characteristics of the total sample and two treatment groups are presented in Table 1. The total per protocol sample was primarily Caucasian (79.6%), with slightly more men (55.2%) than women. The mean age was 58.5 years, and patients had type 2 diabetes for a mean of 9.5 years. Mean HbA1c, and BMI at baseline were 8.3% and 31.5 kg/m², respectively. There were no statistically significant differences at baseline between the two treatment groups in these demographic and clinical variables.

Paired t-tests revealed that both treatment groups demonstrated statistically significant baseline to endpoint change on several of the health outcomes instruments (Table 2). Both the exenatide-treated group and the insulin glargine-treated group demonstrated statistically significant improvement in the DSC-R total score (p < 0.0001 for exenatide and p = 0.0002 insulin glargine), the

### Table 1: Demographic and clinical characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Exenatide (N = 228)</th>
<th>Insulin Glargine (N = 227)</th>
<th>Total (N = 455)</th>
<th>p value&lt;sup&gt;1&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean, SD)</td>
<td>59.4 (8.9)</td>
<td>57.7 (9.4)</td>
<td>58.5 (9.2)</td>
<td>0.06</td>
</tr>
<tr>
<td>Gender (N, % male)</td>
<td>125 (54.8%)</td>
<td>126 (55.5%)</td>
<td>251 (55.2%)</td>
<td>0.92</td>
</tr>
<tr>
<td>Ethnicity (N, %)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>181 (79.4%)</td>
<td>181 (79.7%)</td>
<td>362 (79.6%)</td>
<td>0.69</td>
</tr>
<tr>
<td>Hispanic</td>
<td>37 (16.2%)</td>
<td>35 (15.4%)</td>
<td>72 (15.8%)</td>
<td></td>
</tr>
<tr>
<td>Western Asian</td>
<td>5 (2.2%)</td>
<td>2 (0.9%)</td>
<td>7 (1.5%)</td>
<td></td>
</tr>
<tr>
<td>African Descent</td>
<td>1 (0.4%)</td>
<td>3 (1.3%)</td>
<td>4 (0.9%)</td>
<td></td>
</tr>
<tr>
<td>Native American</td>
<td>0 (0.0%)</td>
<td>1 (0.4%)</td>
<td>1 (0.2%)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>4 (1.8%)</td>
<td>5 (2.2%)</td>
<td>9 (2.0%)</td>
<td>0.21</td>
</tr>
<tr>
<td>Duration of Diabetes in years (mean, SD)</td>
<td>9.7 (5.6)</td>
<td>9.2 (5.9)</td>
<td>9.5 (5.7)</td>
<td>0.55</td>
</tr>
<tr>
<td>HbA1c (mean, SD)</td>
<td>8.3% (0.9%)</td>
<td>8.3% (1.0%)</td>
<td>8.3% (1.0%)</td>
<td>0.53</td>
</tr>
<tr>
<td>BMI (mean kg/m², SD)</td>
<td>31.6 (4.5)</td>
<td>31.4 (4.5)</td>
<td>31.5 (4.5)</td>
<td>0.53</td>
</tr>
</tbody>
</table>

<sup>1</sup>P values are for comparisons between the 2 treatment groups. T-tests were used for continuous variables, and Fisher’s exact tests were used for categorical variables.
DTSQ satisfaction score (p < 0.0001 for both treatment groups), and the SF-36 Vitality subscale (p = 0.005 for exenatide and p < 0.04 for insulin glargine). Both groups also had statistically significant differences between baseline and endpoint scores on several of the DSC-R subscales (psychology: fatigue, psychology: cognitive, ophthalmology, hypoglycemia, hyperglycemia) as well as the hyperglycemia and hypoglycemia items of the DTSQ. In addition, the insulin glargine group demonstrated significant baseline to endpoint change on the EQ-5D index score and the DSC-R cardiology score.

Results of general linear models comparing change in health outcomes between the two treatment groups, controlling for country and baseline score, are presented in Table 3. Results of these models indicate that there were no statistically significant differences between groups in the health outcomes instruments.

Finally, because exenatide has been found to be associated with a higher incidence of nausea than insulin glargine, treatment satisfaction was examined separately among subgroups of patients who experienced nausea at any time during the trial. In the exenatide group, 126 patients reported experiencing nausea at any time during the trial, compared with 22 insulin glargine-treated patients. The subgroup of 126 exenatide-treated patients had mean DTSQ satisfaction scores of 26.9 (SD = 6.8) at baseline and 29.0 (SD = 6.2) at endpoint. A paired t-test found that this improvement (change score = 2.1; SD = 7.4) was statistically significant (t = 3.1, p = 0.002). Findings for the 22 insulin glargine-treated patients were similar. The baseline mean DTSQ satisfaction score was 24.1 (SD = 6.3), and the endpoint score was 30.4 (SD = 4.8). This improvement (change score = 6.2; SD = 6.3; t = 4.6, p = 0.0001)

### Discussion

The current findings add to previous literature suggesting that, among patients whose glucose levels and symptoms are not adequately controlled by oral medications, the improved efficacy offered by the addition of injectable medication may lead to improved treatment satisfaction and quality of life [57,59,60]. This analysis found that both exenatide and insulin glargine were associated with significant improvements in patient-reported outcomes when added to oral medications among patients with type 2 diabetes. Patients in both treatment groups demonstrated statistically significant baseline-to-endpoint improvement in overall treatment satisfaction as measured by the DTSQ and vitality as measured by a subscale of the SF-36. Both groups also had significant reductions in overall symptom impact and problems with several specific symptom domains as measured by the DSC-R (e.g., fatigue, cognition, ophthalmology, hypoglycemia, hyperglycemia). Insulin glargine-treated patients also had statistically significant improvement in overall HRQL as assessed by the EQ-5D. Some studies have reported that patients with type 2 diabetes on oral medications have greater HRQL than patients on insulin [24,51,61-63]. However, current findings are consistent with other studies showing increased HRQL and patient satisfaction after initiating insulin therapy [57,59,60]. Findings were consistent for both drugs despite different side effect profiles and the fact that exenatide was administered twice daily while insulin glargine was administered once daily.

Analyses comparing patient-reported outcomes of the two drugs found no significant differences between treatment groups despite drug differences in several areas such as weight change, side effect profile, and dose frequency. Although exenatide is associated with increased injections and gastrointestinal side effects compared with insulin

### Table 2: Paired t-tests comparing baseline and endpoint scores within each treatment group

<table>
<thead>
<tr>
<th>Health Outcomes Measure (mean, SD)</th>
<th>Baseline</th>
<th>Exenatide Endpoint</th>
<th>p value</th>
<th>Baseline</th>
<th>Insulin Glargine Endpoint</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>DSC-R Overall Score</td>
<td>1.07 (0.83)</td>
<td>0.90 (0.80)</td>
<td>&lt; 0.0001</td>
<td>0.99 (0.78)</td>
<td>0.84 (0.73)</td>
<td>0.0002</td>
</tr>
<tr>
<td>EQ-5D Index Score</td>
<td>0.82 (0.22)</td>
<td>0.85 (0.19)</td>
<td>0.08</td>
<td>0.84 (0.22)</td>
<td>0.87 (0.20)</td>
<td>0.049</td>
</tr>
<tr>
<td>Diabetes Treatment Flexibility Score</td>
<td>60.37 (22.24)</td>
<td>60.48 (22.33)</td>
<td>0.93</td>
<td>58.85 (22.81)</td>
<td>58.95 (23.37)</td>
<td>0.93</td>
</tr>
<tr>
<td>Diabetes Treatment Satisfaction Score</td>
<td>26.41 (7.00)</td>
<td>29.48 (6.12)</td>
<td>&lt; 0.0001</td>
<td>26.31 (6.33)</td>
<td>30.04 (5.21)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>SF-36 Vitality Subscale Score</td>
<td>53.18 (20.87)</td>
<td>56.30 (20.58)</td>
<td>0.005</td>
<td>55.18 (21.35)</td>
<td>57.62 (20.37)</td>
<td>0.04</td>
</tr>
<tr>
<td>DSC-R Psychology: Fatigue Score</td>
<td>1.83 (1.26)</td>
<td>1.49 (1.21)</td>
<td>&lt; 0.0001</td>
<td>1.60 (1.29)</td>
<td>1.34 (1.17)</td>
<td>0.003</td>
</tr>
<tr>
<td>DSC-R Psychology: Cognitive Score</td>
<td>1.18 (1.12)</td>
<td>0.99 (1.08)</td>
<td>0.0006</td>
<td>1.14 (1.09)</td>
<td>0.91 (0.99)</td>
<td>0.0001</td>
</tr>
<tr>
<td>DSC-R Neurology: Pain Score</td>
<td>0.76 (0.98)</td>
<td>0.70 (0.99)</td>
<td>0.21</td>
<td>0.67 (0.90)</td>
<td>0.63 (0.92)</td>
<td>0.49</td>
</tr>
<tr>
<td>DSC-R Neurology: Sensory Score</td>
<td>0.91 (1.07)</td>
<td>0.83 (1.01)</td>
<td>0.10</td>
<td>0.77 (0.94)</td>
<td>0.78 (0.93)</td>
<td>0.83</td>
</tr>
<tr>
<td>DSC-R Cardiology Score</td>
<td>0.78 (0.89)</td>
<td>0.71 (0.86)</td>
<td>0.16</td>
<td>0.73 (0.86)</td>
<td>0.61 (0.80)</td>
<td>0.02</td>
</tr>
<tr>
<td>DSC-R Ophthalmology Score</td>
<td>0.79 (1.00)</td>
<td>0.62 (0.86)</td>
<td>0.003</td>
<td>0.79 (0.98)</td>
<td>0.64 (0.92)</td>
<td>0.006</td>
</tr>
<tr>
<td>DSC-R Hypoglycemia Score</td>
<td>1.09 (1.16)</td>
<td>0.94 (1.09)</td>
<td>0.03</td>
<td>1.10 (1.09)</td>
<td>0.93 (1.00)</td>
<td>0.009</td>
</tr>
<tr>
<td>DSC-R Hyperglycemia Score</td>
<td>1.47 (1.31)</td>
<td>1.07 (1.15)</td>
<td>&lt; 0.0001</td>
<td>1.42 (1.25)</td>
<td>1.02 (1.13)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>DTSQ Frequency High Blood Sugar</td>
<td>3.61 (1.76)</td>
<td>2.19 (1.61)</td>
<td>&lt; 0.0001</td>
<td>3.57 (1.67)</td>
<td>2.11 (1.45)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>DTSQ Frequency Low Blood Sugar</td>
<td>1.02 (1.37)</td>
<td>1.36 (1.56)</td>
<td>0.007</td>
<td>0.80 (1.21)</td>
<td>1.50 (1.43)</td>
<td>&lt; 0.0001</td>
</tr>
</tbody>
</table>
glargine, these potential problems did not appear to result in less patient satisfaction among the exenatide-treated patients. It is possible that, for patients who experienced gastrointestinal side effects from exenatide, the weight reduction benefits associated with the drug outweighed its disadvantages, thus resulting in the observed gains in treatment satisfaction. In addition, although increased dosing frequency often leads to reduced patient satisfaction, this finding is not consistent across all diseases and medications [32]. For example, one previous study conducted with patients who had type 2 diabetes found no treatment satisfaction differences between patients receiving once-daily injections and those receiving twice-daily injections [28]. Both current results and these previous findings suggest that dosing frequency may not be of primary importance to patients receiving injectable medication for type 2 diabetes.

Several aspects of the current study design may have limited the ability to detect true differences in patient experience with these two medications. First, is possible that a naturalistic study conducted with less structure than a clinical trial might yield different findings. For example, if patients have less contact with medical professionals, they might be less adherent to a more complicated dosing regimen. A second possible limitation is the relatively brief study duration. In longer trials of these medications, patients have experienced greater weight change than in this 26-week trial [64], and greater weight change is likely to have a stronger impact on treatment satisfaction and vitality. Third, a larger sample size would provide greater statistical power for detecting statistically significant differences between treatment groups, if in fact there are true differences. Finally, the only HRQL instrument administered in this trial was the brief EQ-5D, which may not be sufficiently sensitive to between-treatment group HRQL differences in this population. Perhaps a multidimensional generic HRQL measure or a condition-specific HRQL measure would have been able to detect differences.

Another factor limiting the interpretation of data is that minimally important differences (MIDs) have not been identified for the three condition-specific instruments used in this study (i.e., DSC-R, DTSQ, and TFS). MID is defined as the smallest change score that a patient would perceive as beneficial [65,66]. For patient-reported outcome measures, the minimally important difference (MID) is used as a guideline to interpret whether improvement can be considered clinically significant or meaningful to patients. Although both treatment groups demonstrated statistically significant change in most of the condition-specific scales, it is not known whether these changes are clinically meaningful.

Previous research has identified MIDs of the two generic instruments used in the current study. MIDs have been suggested to be roughly 3 to 5 for the SF-36 and 0.07 for the EQ-5D, although these MIDs were not derived within samples of patients with diabetes [67,68]. Neither treatment group in the current study met the MID criterion for the EQ-5D. On the SF-36 vitality subscale, the exenatide-treated group changed by 3.12 points, which does exceed the lower estimate of MID for this scale, while the insulin glargine group improved by 2.44 points. However, interpretation of treatment effects should not be made based solely on these generic measures because generic instruments tend to be less responsive to change than condi-

<table>
<thead>
<tr>
<th>Health Outcomes Measure</th>
<th>Exenatide</th>
<th>Insulin Glargine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Score</td>
<td>N</td>
<td>LS Mean  SE</td>
</tr>
<tr>
<td>DSC-R Overall Score</td>
<td>223</td>
<td>-0.16  0.04</td>
</tr>
<tr>
<td>EQ-5D Index Score</td>
<td>217</td>
<td>0.02  0.01</td>
</tr>
<tr>
<td>Diabetes Treatment Flexibility Score</td>
<td>222</td>
<td>0.32  1.28</td>
</tr>
<tr>
<td>Diabetes Treatment Satisfaction Score</td>
<td>213</td>
<td>3.42  0.43</td>
</tr>
<tr>
<td>SF-36 Vitality Subscale Score</td>
<td>223</td>
<td>2.41  1.24</td>
</tr>
<tr>
<td>DSC-R Psychology: Fatigue Score</td>
<td>222</td>
<td>-0.28  0.08</td>
</tr>
<tr>
<td>DSC-R Psychology: Cognitive Score</td>
<td>223</td>
<td>-0.24  0.06</td>
</tr>
<tr>
<td>DSC-R Neurology: Pain Score</td>
<td>222</td>
<td>-0.04  0.06</td>
</tr>
<tr>
<td>DSC-R Neurology: Sensory Score</td>
<td>223</td>
<td>-0.03  0.06</td>
</tr>
<tr>
<td>DSC-R Cardiology Score</td>
<td>223</td>
<td>-0.08  0.06</td>
</tr>
<tr>
<td>DSC-R Ophthalmology Score</td>
<td>222</td>
<td>-0.19  0.06</td>
</tr>
<tr>
<td>DSC-R Hypoglycemia Score</td>
<td>221</td>
<td>-0.20  0.07</td>
</tr>
<tr>
<td>DSC-R Hyperglycemia Score</td>
<td>223</td>
<td>-0.35  0.07</td>
</tr>
<tr>
<td>DTSQ Frequency High Blood Sugar</td>
<td>219</td>
<td>-1.40  0.12</td>
</tr>
<tr>
<td>DTSQ Frequency Low Blood Sugar</td>
<td>218</td>
<td>0.37  0.12</td>
</tr>
</tbody>
</table>

1Comparisons between treatment groups were performed with general linear models. One model was conducted with each health outcomes measure as the dependent variable, controlling for country and baseline score.
tation-specific instruments [37]. Therefore, future research
on MIDs in the three diabetes-specific measures is neces-

sary in order to estimate the clinical significance of

patient-reported improvement in the current study.

Treatment satisfaction is important largely because it is

thought to provide an indication of treatment adherence

[69-71]. In general, patients who are satisfied with their

treatment can be expected to adhere to prescribed treat-

ment regimens more than patients who are unsatisfied.

Therefore, patient satisfaction is necessary in order to

maximize treatment effectiveness. In sum, current results

indicate that both exenatide and insulin glargine were

associated with increased treatment satisfaction and vital-

ity as well as decreased symptom burden.

Competing interests

KS is an employee and stock holder of Eli Lilly and Com-

pany. LM was a paid consultant. AO is an employee and

stock holder of Eli Lilly and Company. KM was a paid

consultant. SK was a paid consultant. RH is an employee

and stock holder of Eli Lilly and Company. RB is an

employee and stock holder of Eli Lilly and Company.

Authors’ contributions

KS formulated the study hypotheses, guided the project,

provided input into data analyses/interpretation, and criti-

cally reviewed the manuscript. LM wrote the manuscript

and provided input into the statistical analyses and data

interpretation. AO provided input into data interpretation

and critically reviewed the manuscript. KM performed sta-

tistical analyses and critically reviewed the manuscript. SK

performed statistical analyses and critically reviewed the

manuscript. RH initiated the quality of life study design,

provided input into the statistical analyses, and critically

reviewed the manuscript. RB provided input into the

study design, provided diabetes-related clinical expertise

to help interpret the results, and critically reviewed the

manuscript. All authors have read and approved the final

manuscript.

Acknowledgements

The authors thank Clare Bradley for her thoughtful review of

this paper; Jodi Shorr for production and editorial assistance;

and Jessica Brewster-Jordan for assistance with literature searching. This study was funded by Eli

Lilly and Company.

References

1. Leidy NK, Revicki DA, Geneste B: Recommendations for evalu-

ating the validity of quality of life claims for labeling and pro-


2. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG:

Exenatide versus insulin glargine in patients with suboptimi-

rally controlled type 2 diabetes: a randomized trial. Ann

Intern Med 2005, 143:559-569.


4. Oiknine R, Bernbaum M, Moordanian A: A critical appraisal of the

role of insulin analogues in the management of diabetes mel-


5. Gerich JE: Insulin glargine: long-acting basal insulin analog for


6. McKeage K, Goa KL: Spotlight on insulin glargine in type 1 and


7. Burke SB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD: Effects

of exenatide (exendin-4) on glycemic control over 30 weeks

in sulfonylurea-treated patients with type 2 diabetes. Diabetes


8. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD:

Effects of exenatide (exendin-4) on glycemic control and

weight over 30 weeks in metformin-treated patients with type


11. Kendall DM, Kim D, Poon T, Han J, Schnabel C, Fineman M, Traut-

mann M, Maggs D: Improvements in cardiovascular risk factors

accompanied sustained effects on glycemia and weight

reduction in patients with type 2 diabetes treated with

exenatide for 82 weeks. In Podium presentation at the 65th Scientific

Sessions of the American Diabetes Association June 10-14; San

Diego; 2005.


MS, Baron AD: Effects of exenatide (exendin-4) on glycemic

control over 30 weeks in patients with type 2 diabetes

treated with metformin and a sulfonylurea. Diabetes Care 2005,

28:1083-1091.


14. Purnell JQ, Weyer C: Weight effect of current and experimental
drugs for diabetes mellitus: from promotion to alleviation


15. de Souza J, Sneek Fj, Colly LF, Deville W, Wijkel D, Heine RJ:

Well-being and symptoms in relation to insulin therapy in


16. Heller S: Weight gain during insulin therapy in patients with


17. Albu J, Raja-Khan N: Evaluation of the association between the EQ-

5D (health-related utility) and body mass index (obesity) in

hospital-treated people with Type 1 diabetes, Type 2 diabetes,

and stock holder of Eli Lilly and Company. RB is an

employee and stock holder of Eli Lilly and Company.

Authors’ contributions

KS formulated the study hypotheses, guided the project,

provided input into data analyses/interpretation, and criti-
cally reviewed the manuscript. LM wrote the manuscript and

provided input into the statistical analyses and data interpre-
tation. AO provided input into data interpretation and cr

itically reviewed the manuscript. KM performed statistical

analyses and critically reviewed the manuscript. SK perfo

rmed statistical analyses and critically reviewed the manusc

ipt. RH initiated the quality of life study design, provided input

into the statistical analyses, and critically reviewed the

manuscript. RB provided input into the study design, pro

vided diabetes-related clinical expertise to help interpret the

results, and critically reviewed the manuscript. All authors have read and approved the final

manuscript.

Acknowledgements

The authors thank Clare Bradley for her thoughtful review of this paper; Jodi Shorr for production and editorial assistance; and Jessica Brewster-Jordan for assistance with literature searching. This study was funded by Eli Lilly and Company.

References


34. Enström CP, Björklof LQ, Larsson B: Health-related quality of life in COPD: why both disease-specific and generic measures should be used. Eur Respir J 2001, 18:69-76.


48. Krabbe P, Weijsen T: Guidelines for analysing and reporting EQ-5D outcomes. In The Measurement and Valuation of Health Sta-